NEURONAX

BIOPOLE CLERMONT LIMAGNE
SAINT BEAUZIRE, 63360
France

Phone: +33 473 44 94 30
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Neuronax is a privately-held biotechnological company focused on the development and discovery of new candidate-drugs for neural repair in cases of traumatic or degenerative disorders of the nervous system. The company focuses particular affections for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function.

Our most advanced product, NX210, which has demonstrated a combined efficacy with neuro-protective and neuro-regenerative activities, is a promising first-in-class candidate that may treat various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Multiple Sclerosis, Alzheimer or Parkinson’s diseases.

A program of preclinical regulatory studies has been completed for this candidate and no apparent toxicity was observed. Thus, IND filing and Phase I/II study in spinal cord injuries is expected to next year.

NEURONAX has developed a cellular platform combining various biological models of nervous cells dedicated to cell-based screening and provides its expertise for evaluation of the effect of an active principle for the nervous system. More recently, expertise of NEURONAX was expanded with the development of specific programs in the regenerative medicine area. Thus, through academic and private collaborations, we are optimizing research grade or clinical grade protocols to expand or differentiate adult stem cells and we are collaborating in preclinical development of particular cell-based therapy.

Last update of this entry: July 10, 2012